Seek Returns

GILD vs. ICLR: Gilead Sciences vs. ICON Stock Comparison

How do Gilead Sciences (GILD) and ICON (ICLR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Gilead Sciences (GILD) and ICON (ICLR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while ICLR is classified in Life Sciences Tools & Services.

Company profile comparison for Gilead Sciences (GILD) and ICON (ICLR)
Profile ItemGILDICLR
NameGilead Sciences Inc.ICON plc
Country/RegionUnited StatesIreland
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyLife Sciences Tools & Services
GICS Sub-IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization207.00 billion USD15.34 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJanuary 22, 1992May 15, 1998
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

GILD
ICLR
GSPC
Loading price history…
Gilead Sciences (GILD) vs. ICON (ICLR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Gilead Sciences (GILD) and ICON (ICLR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Gilead Sciences (GILD) and ICON (ICLR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Gilead Sciences (GILD) and ICON (ICLR)
MetricGILDICLR
Total Return (1Y)45.69%30.55%
Total Return (3Y, Annualized)35.30%-6.05%
Total Return (5Y, Annualized)25.00%-5.40%

Risk Profile

Drawdown History

GILD
ICLR
GSPC
Loading price history…
Gilead Sciences (GILD) vs. ICON (ICLR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Gilead Sciences (GILD) and ICON (ICLR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Gilead Sciences (GILD) and ICON (ICLR)
MetricGILDICLR
Volatility (1Y, Annualized)27.57%68.62%
Beta (5Y)0.361.17
Max Drawdown (5Y)-26.59%-76.87%
Avg. Volume (3M)5.98M943.50K

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
GILD and ICLR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Gilead Sciences (GILD) and ICON (ICLR)
MetricGILDICLR
Sharpe Ratio (1Y)1.500.38
Sortino Ratio (1Y)2.480.52

Profitability

ROE (TTM)

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile ICON (ICLR) reports 4.70%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-22.45%

Max
109.18%
Q3
6.23%
GILD
-22.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70%

Max
109.18%
Q3
6.23%
ICLR
4.70%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Gilead Sciences (GILD) vs. ICON (ICLR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile ICON (ICLR) reports 5.26%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.46%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
GILD
-12.46%
Min
-17.05%

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.26%

Max
18.05%
ICLR
5.26%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Gilead Sciences (GILD) vs. ICON (ICLR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Gilead Sciences (GILD) at 42.43% operates in the top operating margin quartile, ahead of ICON (ICLR) at 10.73%, which runs around its industry’s norm.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

42.43%

Max
83.12%
GILD
42.43%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.73%

Max
83.12%
Q3
14.77%
ICLR
10.73%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Gilead Sciences (GILD) vs. ICON (ICLR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Gilead Sciences (GILD) and ICON (ICLR)
MetricGILDICLR
ROE (TTM)-22.45%4.70%
ROA (TTM)13.47%0.85%
Net Margin (TTM)-12.46%5.26%
Operating Margin (TTM)42.43%10.73%
Gross Margin (TTM)79.95%23.44%

Growth

Revenue Growth

Both Gilead Sciences (GILD) at 2.39% and ICON (ICLR) at 0.76% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Gilead Sciences (GILD) vs. ICON (ICLR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Gilead Sciences (GILD) at 1,684.21% delivers above-range EPS growth, while ICON (ICLR) at -71.56% falls into the bottom quartile — a wide split in earnings momentum.

Loading chart…
Gilead Sciences (GILD) vs. ICON (ICLR): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Gilead Sciences (GILD) and ICON (ICLR)
MetricGILDICLR
Revenue Growth (YoY)2.39%0.76%
Revenue Growth (3Y CAGR)2.57%2.15%
EPS Growth (YoY)1,684.21%-71.56%
EPS Growth (3Y CAGR)23.04%-23.82%

Financial Strength

Current Ratio (MRQ)

Both Gilead Sciences (GILD) at 1.38 and ICON (ICLR) at 1.32 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GILD
1.38
Min
0.10

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.32

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ICLR
1.32
Min
0.10
Loading chart…
Gilead Sciences (GILD) vs. ICON (ICLR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

ICON (ICLR) at 0.38 is near its industry mid-range for debt-to-equity ratio, while Gilead Sciences (GILD) at 2.02 sits above its benchmark range, pointing to a heavier debt load relative to equity.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.02

GILD
2.02
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max
1.42
Q3
0.65
ICLR
0.38
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Gilead Sciences (GILD) vs. ICON (ICLR): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Gilead Sciences (GILD) and ICON (ICLR)
MetricGILDICLR
Current Ratio (MRQ)1.381.32
Debt / Equity (MRQ)2.020.38
Net Debt / EBITDA1.255.55

Dividends

Dividend Yield (TTM)

ICON (ICLR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a yield of 1.94%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

GILD
1.94%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Gilead Sciences (GILD) vs. ICON (ICLR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

ICON (ICLR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a payout of 43.46%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.46%

GILD
43.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Gilead Sciences (GILD) vs. ICON (ICLR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Gilead Sciences (GILD) and ICON (ICLR)
MetricGILDICLR
Dividend Yield (TTM)1.94%0.00%
Dividend Payout Ratio (TTM)43.46%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: ICON (ICLR) trades at 81.90 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
GILD
--

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

81.90

Max
85.34
ICLR
81.90
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Gilead Sciences (GILD) vs. ICON (ICLR): GILD does not report P/E ratio, so it has no value marker; ICLR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

ICON (ICLR) at 1.86 sits in the cheaper P/S ratio quartile while Gilead Sciences (GILD) at 6.68 prices around its industry’s middle — ICLR costs less per dollar of sales, though read it alongside growth and margins.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
GILD
6.68
Q1
3.01
Min
0.01

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.86

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
ICLR
1.86
Min
0.01
Loading chart…
Gilead Sciences (GILD) vs. ICON (ICLR): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

ICON (ICLR) at 1.68 sits in the lower P/B ratio quartile relative to book while Gilead Sciences (GILD) at 15.88 prices above its industry range — a wide valuation gap against assets.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.88

GILD
15.88
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.68

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
ICLR
1.68
Min
-5.59
Loading chart…
Gilead Sciences (GILD) vs. ICON (ICLR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Gilead Sciences (GILD) and ICON (ICLR)
MetricGILDICLR
P/E Ratio (TTM)--81.90
P/S Ratio (TTM)6.681.86
P/B Ratio (MRQ)15.881.68
Free Cash Flow Yield (TTM)5.16%3.51%